ClinicalTrials.gg
Not yet recruitingNCT07594028Updated May 18, 2026

Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours

A Phase 1/2 interventional study of SCTB41+SCTB39-1 in Advanced Malignant Solid Tumor, sponsored by Sinocelltech Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
126
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39-1with or without standard therapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

02

Conditions studied

  • Advanced Malignant Solid Tumor

Keywords

  • advanced malignant solid tumor
03

In context

Lead sponsor

Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form (ICF);
  2. Male or female, ≥ 18 years and ≤ 75 years old;
  3. Survival duration more than 3 months;
  4. score ≤ 1 point;
  5. or cytologically confirmed diagnosis of advanced malignant solid tumour;
  6. At least one measurable tumor lession according to v1.1;
  7. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. Has participated in another clinical study within 4 weeks prior to the first dose;
  2. Has previously received other immunotherapies other than PD-(L)1 inhibitors;
  3. Other diagnosed within 5 years prior to the enrollment;
  4. Participants with brainstem, meningeal, spinal , or compression; active central nervous system metastases;
  5. Significant bleeding risk;
  6. Presence of pleural effusion, peritoneal effusion, or ascites;
  7. Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment;
  8. History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs;
  9. Presence of any active disease or a history of autoimmune disease with an expected recurrence;
  10. History of severe allergies, severe drug allergies (including unapproved drugs);
  11. History of organ transplantation or stem cell transplantation;
  12. Need for drugs within 2 weeks prior to enrollment or anticipated during the study;
  13. Pregnant or breastfeeding female.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    SCTB41+SCTB39-1

    SCTB41 plus SCTB39-1 of different doses, IV, every 3 weeks

    Drug: SCTB41+SCTB39-1

Interventions

  • DrugSCTB41+SCTB39-1

    SCTB41 plus SCTB39-1 of different doses, IV, every 3 weeks

06

What researchers measure

Primary outcomes

  1. Dose-Limiting toxicity(DLT)

    Incidence of dose-limiting toxicities up to the Day 21 visit

    Time frame: From Day 0 up to Day 21

  2. Objective response rate (ORR)

    The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.

    Time frame: Up to 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    The DCR is defined as the proportion of subjects with CR, PR, or SD based on RECIST Version 1.1.

    Time frame: Up to 2 years

  2. Progression-free survival (PFS)

    The PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  3. Overall survival (OS)

    Overall survival is defined as the time from the start of treatment until death due to any cause.

    Time frame: Up to 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 18, 2026
StartEst.
May 30, 2026
Primary completionEst.
May 30, 2029
CompletionEst.
May 30, 2029
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07594028
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
May 18, 2026
Start date
May 30, 2026 (estimated)
Primary completion
May 30, 2029 (estimated)
Completion
May 30, 2029 (estimated)
Last update
May 18, 2026

Study contacts

Dongyang Gao, Doctor
Contact
dongyang_gao@sinocelltech.com
+86-010-58628288
jiang
principal investigator · Cancer Hospital Chinese Academy of Medical Science Recruiting Beijing, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion